Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
    Most visited pages

        PHARMATHEN HELLENIC PHARMA R&D

        Signature(s)

        Amount
        € 25,000,000
        Countries
        Sector(s)
        Greece : € 25,000,000
        Industry : € 25,000,000
        Signature date(s)
        17/12/2010 : € 25,000,000

        Summary sheet

        Release date
        27 September 2010
        Status
        Reference
        Signed | 17/12/2010
        20090147
        Project name
        Promoter - financial intermediary
        Pharmathen Hellenic Pharma R&D

        Pharmathen S.A.

        Proposed EIB finance (Approximate amount)
        Total cost (Approximate amount)
        EUR 25 million.
        The promoter’s budgeted R&D expenses for the years 2010-2013, i.e. the project costs, are about EUR 55 million.
        Location
        Sector(s)
        Description
        Objectives

        The project concerns the promoter’s R&D activities from 2010 to 2013, related to the development of Active Pharmaceutical Ingredients (API) for generic pharmaceuticals, including new manufacturing processes.

        The project objectives are to enlarge the company’s generic product offering and develop new drug delivery techniques for originator drugs approaching patent expiry, with the aim of extending protection from generic competition through life-cycle management. Apart from research and development, the project also comprises regulatory approval processes.

        Environmental aspects
        Procurement

        The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres etc. Thus an Environmental Impact Assessment (EIA) according to the EU Directive 97/11, as amended by Directive 2003/35, is not required.

        The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.

        Comments

        Loan foreseen under the Risk Sharing Finance Facility (RSFF).

        Disclaimer

        Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
        They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

        General enquiries and comments

        The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
        Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
        Alternatively, the EIB can be contacted through its external offices.
        Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

        Media enquiries

        Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

        Complaints mechanism

        Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

        Zero tolerance against fraud and corruption

        The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

        Related publications